Current Report Filing (8-k)
14 August 2019 - 10:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 14, 2019
NeuBase Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
|
001-35963
|
46-5622433
|
(State
or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification No.)
|
700
Technology Drive, Pittsburgh, PA
|
15219
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(646)
450-1790
|
|
(Registrant's
Telephone Number, Including Area Code)
|
|
N/A
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
NBSE
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17
CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02
Results of Operations and Financial Condition.
On
August 14, 2019, we issued a press release reporting our financial results for the third quarter ended June 30, 2019 and providing
a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form
8-K and incorporated herein by reference.
In
accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No
|
|
Description
|
99.1
|
|
Press release issued
August 14, 2019, reporting financial results for the third quarter ended June 30, 2019 and providing a corporate update.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NEUBASE
THERAPEUTICS, INC.
|
|
|
|
|
Date:
August 14, 2019
|
By:
|
/s/
Dietrich A. Stephan
|
|
|
|
Dietrich A. Stephan, Ph.D.
|
|
|
President
& Chief Executive Officer
(Principal Executive Officer)
|
Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Ohr Pharmaceuticals, Inc. (NASDAQ): 0 Nachrichtenartikel
Weitere Neubase Therapeutics, Inc. News-Artikel